ReviewNature reviews. Neurology2022
Emerging therapies to target CNS pathophysiology in multiple sclerosis.
Review in Nature reviews. Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer's disease and multiple sclerosis: a systematic review.Frontiers in immunology · 2023Pooled it
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- Assisted Reproduction Therapy in Patients with Multiple Sclerosis: Narrative Review and Practical Recommendations.Healthcare (Basel, Switzerland) · 2025Review
- The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis.International journal of molecular sciences · 2025Review
- Gut dysbiosis in multiple sclerosis patients: a comparative analysis in fecal samples.Scientific reports · 2025Article
- SARS-CoV-2 Is Linked to Brain Volume Loss in Multiple Sclerosis.Annals of clinical and translational neurology · 2025Article
- Bruton Tyrosine Kinase in Lesions of Multiple Sclerosis and 3 of Its Models.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- TGFα controls checkpoints in CNS resident and infiltrating immune cells to promote resolution of inflammation.Nature communications · 2025Article
- Pathogenetic Involvement of Autophagy and Mitophagy in Primary Progressive Multiple Sclerosis.Journal of cellular and molecular medicine · 2025Article
- Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.Journal of neurology · 2025Review
- The inflammatory APRIL (a proliferation-inducing ligand) antagonizes chondroitin sulphate proteoglycans to promote axonal growth and myelination.Brain communications · 2025Article
- A Defined Diet Combined with Sonicated Inoculum Provides a High Incidence, Moderate Severity Form of Experimental Autoimmune Encephalomyelitis (EAE).ACS pharmacology & translational science · 2024Article
- Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.Annals of neurology · 2024Article
- Article
- Emerging imaging markers in radiologically isolated syndrome: implications for earlier treatment initiation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- The pressing need for imaging biomarkers of disability progression in multiple sclerosis.European radiology · 2024Article
- Review
- The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology.Nature immunology · 2024Article
- Deeply 3D-T1-TFE hypointense voxels are characteristic of phase-rim lesions in multiple sclerosis.European radiology · 2024Article
- From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapidly evolving therapeutic landscape of multiple sclerosis (MS) has contributed to paradigm shifts in our understanding of the biological mechanisms that contribute to CNS injury and in treatment philosophies. Opportunities remain to further improve treatment of relapsing-remitting MS, but two major therapeutic gaps are the limiting of progressive disease mechanisms and the repair of CNS injury. In this Review, we provide an overview of selected emerging therapies that predominantly target processes within the CNS that are thought to be involved in limiting non-relapsing, progressive disease injury or promoting tissue repair. Among these, we consider agents that modulate adaptive and innate CNS-compartmentalized inflammation, which can be mediated by infiltrating immune cells and/or resident CNS cells, including microglia and astrocytes. We also discuss agents that target degenerative disease mechanisms, agents that might confer neuroprotection, and agents that create a more favourable environment for or actively contribute to oligodendrocyte precursor cell differentiation, remyelination and axonal regeneration. We focus on agents that are novel for MS, that are known to or are presumed to penetrate the CNS, and that have already entered early stages of development in MS clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.